Comparison of cerebral safety after atrial fibrillation using pulsed field and thermal ablation: Results of the neurological assessment subgroup in the ADVENT trial
- PMID: 38823667
- DOI: 10.1016/j.hrthm.2024.05.048
Comparison of cerebral safety after atrial fibrillation using pulsed field and thermal ablation: Results of the neurological assessment subgroup in the ADVENT trial
Abstract
Background: Atrial fibrillation (AF) ablation carries the risk of silent cerebral event (SCE) and silent cerebral lesion (SCL). Although "silent," these may have long-term clinical implications and are challenging to study as postprocedural magnetic resonance imaging (MRI) is not standard of care.
Objective: The neurological assessment subgroup (NAS) of ADVENT compared cerebral effects of pulsed field ablation (PFA) with standard-of-care thermal ablation.
Methods: The NAS included consecutive randomized PFA and thermal ablation patients who received postprocedural brain MRI 12-48 hours after ablation. Patients with apparent SCE or SCL findings underwent a modified Rankin scale assessment. MRI images were subsequently reviewed by a blinded brain imaging core laboratory.
Results: In total, 77 patients with paroxysmal AF were enrolled at 6 centers; 71 had analyzable scans (34 PFA; 37 thermal ablation). Through individual center review, 6 PFA and 4 thermal scans were identified as SCE/SCL positive, of which 3 PFA and 0 thermal SCE/SCL findings were confirmed by a blinded core laboratory. MRI findings revealed 1 patient with 2- to 4-mm SCEs, 1 patient with a 3-mm SCE, and 1 patient with 2 SCLs (5.5 mm and 11 mm). All modified Rankin scale and National Institutes of Health Stroke Scale scores were 0 before discharge and at 90-day follow-up. There were only 2 neurological safety events (1 transient ischemic attack [PFA] and 1 stroke [thermal ablation]) in the ADVENT study, neither of which was part of the NAS.
Conclusion: The ADVENT trial provides the first prospective, randomized data on the cerebral impact of PFA and thermal ablation of AF. Incidence of SCE/SCL after ablation in the NAS was low.
Keywords: Atrial fibrillation; Brain; Magnetic resonance imaging; Pulsed field ablation; SCE/SCL.
Copyright © 2024 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures C.P., consultant for Boston Scientific. E.P.G., consultant to Farapulse Inc and serves as an unpaid consultant to Boston Scientific Inc; lecture honoraria from Boston Scientific Inc. S.K.G., consultant for Medtronic and Boston Scientific. J.W., consultant for Biosense Webster, Abbott, Boston Scientific, and Thermedical. C.W., equity in inHEART and SoloPace, intellectual property with ensoETM and SoloPace; travel funds from Abbott and AtriCure. A.N., consultant for Abbott, Biosense Webster, and Boston Scientific. J.W.L., consultant to and received equity from Farapulse Inc (now divested) and serves as a consultant to Boston Scientific Inc. M.M., consultant for Boston Scientific. V.Y.R., consultant to and received equity from Farapulse Inc (now divested), and receives grant support from and serves as a consultant to Boston Scientific Inc; and unrelated to this manuscript, V.Y.R. has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera-Medtronic, Anumana, Apama Medical–Boston Scientific, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT/AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNovA EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics–Medtronic, EpiEP, Eximo, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, Valcare; and unrelated to this work, V.Y.R. has served as a consultant for Abbott, Adagio Medical, AtriAN, Biosense-Webster, BioTel Heart, Biotronik, Cairdac, Cardiofocus, Cardionomic, CoreMap, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Novartis, Philips, Pulse Biosciences; and unrelated to this work, V.Y.R. has equity in Atraverse, Manual Surgical Sciences, Newpace, Nyra Medical, Surecor, and Vizaramed.
Similar articles
-
Cerebral safety after pulsed field ablation for paroxysmal atrial fibrillation.Heart Rhythm. 2022 Nov;19(11):1813-1818. doi: 10.1016/j.hrthm.2022.06.018. Epub 2022 Jun 17. Heart Rhythm. 2022. PMID: 35718318
-
Silent cerebral events/lesions related to atrial fibrillation ablation: a clinical review.J Cardiovasc Electrophysiol. 2015 Apr;26(4):455-463. doi: 10.1111/jce.12608. Epub 2015 Feb 11. J Cardiovasc Electrophysiol. 2015. PMID: 25556518 Review.
-
Association between left atrial low-voltage area, serum apoptosis, and fibrosis biomarkers and incidence of silent cerebral events after catheter ablation of atrial fibrillation.J Interv Card Electrophysiol. 2015 Oct;44(1):55-62. doi: 10.1007/s10840-015-0020-6. Epub 2015 Jun 6. J Interv Card Electrophysiol. 2015. PMID: 26048130
-
Safety aspects of very high power very short duration atrial fibrillation ablation using a modified radiofrequency RF-generator: Single-center experience.J Cardiovasc Electrophysiol. 2022 May;33(5):920-927. doi: 10.1111/jce.15433. Epub 2022 Mar 11. J Cardiovasc Electrophysiol. 2022. PMID: 35233883
-
Incidence of silent cerebral events detected by MRI in patients with atrial fibrillation undergoing pulsed field ablation vs thermal ablation: A systematic review and network meta-analysis.Heart Rhythm. 2025 Apr 11:S1547-5271(25)02315-X. doi: 10.1016/j.hrthm.2025.04.008. Online ahead of print. Heart Rhythm. 2025. PMID: 40221109 Review.
Cited by
-
Biophysics and Clinical Effectiveness of Irreversible Electroporation for Catheter Ablation of Atrial Fibrillation.J Cardiovasc Dev Dis. 2025 Jun 7;12(6):218. doi: 10.3390/jcdd12060218. J Cardiovasc Dev Dis. 2025. PMID: 40558653 Free PMC article. Review.
-
Concise Guidelines of the European Cardiac Arrhythmias Society (ECAS) on "Catheter Ablation of Atrial Fibrillation".J Cardiovasc Electrophysiol. 2025 May;36(5):1076-1099. doi: 10.1111/jce.16561. Epub 2025 Mar 4. J Cardiovasc Electrophysiol. 2025. PMID: 40035661 Free PMC article. No abstract available.
-
Pulsed Field Ablation: A Comprehensive Update.J Clin Med. 2024 Sep 1;13(17):5191. doi: 10.3390/jcm13175191. J Clin Med. 2024. PMID: 39274404 Free PMC article. Review.
-
A Year in Review: Atrial Fibrillation 2024.J Innov Card Rhythm Manag. 2025 Jan 15;16(1):6136-6140. doi: 10.19102/icrm.2025.16016. eCollection 2025 Jan. J Innov Card Rhythm Manag. 2025. PMID: 39897725 Free PMC article. No abstract available.
-
Intraprocedural activated clotting time and heparin dosage in pulsed field ablation of paroxysmal atrial fibrillation.Front Cardiovasc Med. 2025 Feb 24;12:1501716. doi: 10.3389/fcvm.2025.1501716. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40066349 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous